LATHAM, N.Y.--(BUSINESS WIRE)-- AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, ...
After kicking off 2024 with the news that it had begun restructuring its manufacturing footprint, and following last summer’s sell-off of two product portfolios, AngioDynamics is putting more of its ...
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO): Fiscal Year 2024 Third Quarter Highlights AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company ...
AngioDynamics has announced it has received FDA clearance for a new peripherally inserted central catheter, according to a news release. The company’s BioFlo peripherally inserted central catheters ...
A month has gone by since the last earnings report for AngioDynamics (ANGO). Shares have lost about 3.9% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...
Good morning and welcome to the AngioDynamics fiscal year 2024 third quarter earnings call. At this time, all participants are in a listen-only mode. A question and answer session will follow the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results